Codiak BioSciences, Inc.

General Information
Business:

We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases (cancer, neuromuscular disease and infectious diseases) with high unmet medical need. Exosomes are intercellular transfer mechanisms; they have emerged in recent years as a compelling potential drug delivery vehicle.

There have been no approved exosome-based therapeutics to date.

Our lead product candidates are being developed to treat solid tumors. We expect to enter clinical trials in the second half of 2020.

 

 

Industry: Pharmaceuticals
Employees: 101
Founded: 2015
Contact Information
Address 35 Cambridge Park Drive, Suite 500 Cambridge, MA 02140
Phone Number (617) 949-4100
Web Address http://www.codiakbio.com/
View Prospectus: Codiak BioSciences, Inc.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-80.7 mil (last 12 months)
IPO Profile
Symbol CDAK
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Goldman Sachs/ Evercore ISI/ William Blair/ Wedbush PacGrow
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change